Phase I Clinical Trial of Topotecan and Pegylated Liposomal Doxorubicin

REFERENCES

• Rubex (Doxorubicin Hydrochloride for Injection, USP) [Package Insert]. MeadJohnson Oncology Products, Princeton, NJ 2001
   Google Scholar
• Tejada-Berges T., Granai C. O., Gordinier M., Gajewski W. Caelyx/doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev. Anticancer Ther. 2002; 2(2)143–150, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Vaage J., Donovan D., Mayhew E., Abra R., Huang A. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72(12)3671–3675, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Williams S. S., Alosco T. R., Mayhew E., Lasic D. D., Martin F. J., Bankert R. B. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. 1993; 53(17)3964–3967, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Libson E., Muggia F. M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995; 13(7)1777–1785, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Muggia F. M., Hainsworth J. D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F. A., Morrow C. P., Paradiso L. J., Liang L. J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997; 15(3)987–993, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ranson M. R., Carmichael J., O'Byrne K., Stewart S., Smith D., Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 1997; 15(10)3185–3191, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Judson I., Radford J. A., Harris M., Blay J. Y., van Hoesel Q., le Cesne A., van Oosterom A. T., Clemons M. J., Kamby C., Hermans C., Whittaker J., Donato di Paola E., Verweij J., Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 2001; 37(7)870–877, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gordon A. N., Fleagle J. T., Guthrie D., Parkin D. E., Gore M. E., Lacave A. J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 2001; 19(14)3312–3322, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pratesi G., Tortoreto M., Corti C., Giardini R., Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Br. J. Cancer 1995; 71(3)525–528, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Burris H. A., 3rd, Hanauske A. R., Johnson R. K., Marshall M. H., Kuhn J. G., Hilsenbeck S. G., Von Hoff D. D. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. 1992; 84(23)1816–1820, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I., Broom C., Scarabelli C., Davidson N., Spanczynski M., Bolis G., Malmström H., Coleman R., Fields S. C., Heron J. F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 1997; 15(6)2183–2193, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Noda K., Sasaki H., Yamamoto K., Yamamoto T., Nishimura R., Sugiyama T., Nakajima H. Phase II trial of topotecan for cervical cancer of the uterus. Proc. Am. Soc. Clin. Oncol. 1996; 15: 280, 754[CSA]
   Google Scholar
• Ardizzoni A., Hansen H., Dombernowsky P., Gamucci T., Kaplan S., Postmus P., Giaccone G., Schaefer B., Wanders J., Verweij J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease The european organisation for research and treatment of cancer early clinical studies group and new drug development office, and the lung cancer cooperative group. J. Clin. Oncol. 1997; 15(5)2090–2096, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Jensen P. B., Holm B., Sorensen M., Christensen I. J., Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Br. J. Cancer 1997; 75(6)869–877, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cheng M. F., Chatterjee S., Berger N. A. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol. Res. 1994; 6(6)269–279, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kaufmann S. H., Peereboom D., Buckwalter C. A., Svingen P. A., Grochow L. B., Donehower R. C., Rowinsky E. K. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J. Natl. Cancer Inst. 1996; 88(11)734–741, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Alberts D. S., Garcia D. J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54: 30–35, suppl. 4[PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tolcher A. W., O'Shaughnessy J. A., Weiss R. B., Zujewski J., Myhand R. C., Schneider E., Hakim F., Gress R., Goldspiel B., Noone M. H., Brewster L. R., Gossard M. R., Cowan K. H. A Phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin. Cancer Res. 1997; 3(5)755–760, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Seiden M. V., Ng S. W., Supko J. G., Ryan D. P., Clark J. W., Lynch T., Huang K. C., Kwiatkowski D., Skarin A., Eder J. P., Jr. A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin. Cancer Res. 2002; 8(3)691–697, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ryan C. W., Fleming G. F., Janisch L., Ratain M. J. A Phase I study of liposomal oxorubicin (Doxil) with topotecan. Am. J. Clin. Oncol. 2000; 23(3)297–300, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Geertsen P., Stroyer I., Herrstedt J., Hansen S. W. Phase I study of topotecan (T) and pegylated liposomal doxorubicin (caelyx) in patients (pts) with progressive ovarian cancer with in 12 months after first-line platinum-paclitaxel containing chemotherapy. Proc. Am. Soc. Clin. Oncol. 2001; 20: 2522, 193b[CSA]
   Google Scholar
• Pautier P., Sr., Germann N., Jr., Faivre S., Jr., Gross M., Jourdan R., Lhomme C., Djazouli K., Armand J., Boutin Tranchant M., Ady Vago N., Raymond E. Phase I study of caelyx (KLX-stealth stabilized liposomal doxorubicin-doxil) in combination with topotecan (TPT). Proc. Am. Soc. Clin. Oncol. 2000; 19: 910, 232a[CSA]
   Google Scholar
• Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 2000; 79(1)116–119, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Miller D. S., Blessing J. A., Lentz S. S., Forest W., Mannel R. S. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian or primary peritoneal cancer: a gynecologic oncology group study. 33rd Annual Meeting of the Society of Gynecologic Oncologists. March, 2–72001
   Google Scholar
• Stebbing J., Gaya A. Pegylated liposomal doxorubicin (caelyx) in recurrent ovarian cancer. Cancer Treat Rev. 2002; 28(2)121–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Herzog T. J. Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002; 7: 3–10, suppl. 5[PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hamilton A., Hochster H., Rosenthal M., Chachoua A., Sorich J., Cahr M., Muggia F. Continuous infustion topotecan (TP-CI) with doxil (DX): A Phase I study of dual topoisomerase inhibition. Proc. Am. Soc. Clin. Oncol. 2000; 19(200a)777, [CSA]
   Google Scholar